Aeterna Zentaris - AEZS Profit before deduction of interest, taxes, depreciation and amortization

Strict regulatory oversight is curbing the expansion of Aeterna Zentaris (AEZS), yet historical EBITDA_Co data demonstrates real growth dynamics. The value captures this metric, confirming the effectiveness of the IP licensing model in minimizing costs. Business stability relies on patent ownership and the attainment of orphan drug designations, which guarantees a flow of payments from major partners.

This indicator captures the actual cash flow from core operations, excluding accounting accruals and demonstrating the business's factual ability to generate cash. By analyzing the cash EBITDA trend, an investor assesses the financial stability of Aeterna Zentaris (AEZS), which, given the full outsourcing of synthesis and testing, depends critically on the operational efficiency of external contractors and the stability of vendor payments.